Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: June 2014

Chapter 45 - Parkinson's disease and other movement disorders

from Section 7 - Disease-specific neurorehabilitation systems

Related content

Powered by UNSILO

References

1. Schrag A. Epidemiology of movement disorders. In Jankovic JJ, Tolosa E. eds. Parkinson's Disease and Movement Disorders. 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002; 73–89.
2. De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the Euro–Parkinson collaborative study. J Neurol Neurosurg Psychiatry 1997; 62: 10–15.
3. Muller J, Kiechl S, Wenning GK, et al. The prevalence of primary dystonia in the general community. Neurology 2002; 59: 941–3.
4. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord 1998; 13: 5–10.
5. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Neurology 2000; 54: 1064–8.
6. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197–211.
7. Biskup S, Gerlag M, Kupsch A, et al. Genes associated with Parkinson syndrome. J Neurol 2008; 255: 8–17.
8. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–7.
9. Khan NL, Graham E, Critchley P, et al. Parkinson's disease: a phenotypic study of a large case series. Brain 2003; 126: 1279–92.
10. Van De Warrenburg BP, Lammens M, Luecking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001; 56: 555–7.
11. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–52.
12. Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861–70.
13. Schrag A, Good CD, Miszkiel K. et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697–702.
14. Morrish PK, Sawle GV, Brooks DJ. Regional changes in [18F] dopa metabolism in the striatum in Parkinson's disease. Brain 1996; 119: 2097–103.
15. Brooks DJ. Movement disorders. In Jankovic JJ, Tolosa E, eds. Functional Imaging in Parkinson's Disease and Movement Disorders. 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002; 610–31.
16. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334: 71–6.
17. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001; 58: 1611–15.
18. Hoehn MM, Yahr MDP. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–42.
19. Muller J, Wenning GK, Jellinger K, et al. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology 2000; 55: 888–91.
20. Hely MA, Reid WGJ, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
21. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044–53.
22. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484–91.
23. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2009; 15: S97–100.
24. Merola A, Zibetti M, Angrisano S, et al. Comparison of subthalamic nucleus deep brain stimulation and duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011; 26: 664–70.
25. Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord 2011; 4: 587–98.
26. Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001; 56: 548–51.
27. Deusch G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896–908.
28. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002; 73: 529–34.
29. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99–102.
30. Bain PG, Findley LJ, Thompson PD, et al. A study of hereditary essential tremor. Brain 1994; 117: 805–24.
31. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Ann Neurol 1994; 35: 717–23.
32. Critchley M. Arteriosclerotic parkinsonism. Brain 1929; 52: 23–83.
33. Zijlmans JC, Daniel SE, Hughes AJ, et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 2004; 9: 630–40.
34. Fitzgerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord 1989; 4: 249–60.
35. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19–28.
36. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–24.
37. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229–37.
38. Tolosa E, Valldeoriola F, Pastor P. Progressive supranuclear palsy. In Jankovic JJ, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2002; 73–89.
39. Gai WP, Power JH, Blumbergs PC, et al. Multiple-system atrophy: a new alpha-synuclein disease? Lancet 1998; 352: 547–8.
40. Wenning GK, Ben-Shlomo Y, Maglhaes M, et al. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1995; 117: 835–45.
41. Weiner WJ, Singer C. Parkinson's disease and non-pharmacological treatment programs. J Am Geriatr Soc 1989; 37: 359–63.
42. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17: 156–66.
43. Ward CD. Rehabilitation in Parkinson's disease and parkinsonism. In Meara J, Koller WC, eds. Parkinson's Disease and Parkinsonism in the Elderly. Cambridge: Cambridge University Press, 2000; 165–84.
44. Keus SHJ, Munneke M, Nijkrake MJ, et al. Physical therapy in Parkinson's disease: evolution and future challenges. Mov Disord 2009; 1: 1–14.
45. Morris ME. Locomotor training in people with Parkinson disease. Phys Ther 2006; 86: 1426–35.
46. Farley B, Koshland GF. Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson's disease. Exp Brain Res 2005; 167: 462–7.
47. Ebersbach G, Ebersbach A, Edler D, et al. Comparing exercise in Parkinson's disease–the Berlin LSVT®BIG study. Mov Disord 2010; 12: 1902–8.
48. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–13.
49. Giladi N, McMahon D, Przedborski S, et al. Motor blocks in Parkinson's disease. Neurology 1992; 42: 333–9.
50. Marsden CD. The mysterious motor function of the basal ganglia: the Robert Wartenberg lecture. Neurology 1982; 32: 514–39.
51. Brotchie P, Iansek R, Horne MK. Motor function of the monkey globus pallidus. 1. Neuronal discharge and parameters of movement. Brain 1991; 114: 1667–83.
52. Georgiou N, Iansek R, Bradshaw J, et al. An evaluation of the role of internal cues in the pathogenesis of parkinsonian hypokinesia. Brain 1993; 116: 1575–87.
53. Bloem BR, Hausdorff JM, Visser JE, et al. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004; 19: 871–84.
54. Abbruzzese G, Berardelli A. Sensorimotor integration in movement disorders. Mov Disord 2003; 18: 231–40.
55. Klockgether T, Dichgans J. Visual control of arm movements in Parkinson's disease. Mov Disord 1994; 9: 48–56.
56. Klockgether T, Borutta M, Rapp H, et al. A defect of kinesthesia in Parkinson's disease. Mov Disord 1995; 10: 460–5.
57. Moore AP. Impaired sensorimotor integration in parkinsonism and dyskinesias: a role of corollary discharges? J Neurol Neurosurg Psychiatry 1987; 50: 544–52.
58. Demirci M, Grill S, McShane L, et al. A mismatch between kinaesthetic and visual perception in Parkinson's disease. Ann Neurol 1997; 41: 781–8.
59. Fellows SJ, Noth J, Schwarz M. Precision grip and Parkinson's disease. Brain 1998; 121: 1771–84.
60. Rubinstein TC, Giladi N, Hausdorff JM. The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson's disease. Mov Disord 2002; 17: 1148–60.
61. Marchese R, Diverio M, Zucchi F, et al. The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. Mov Disord 2000; 15: 879–83.
62. Morris ME, Iansek R, Matyas TA, et al. Stride length regulation in Parkinson's disease. Normalisation strategies and underlying mechanisms. Brain 1996; 119: 551–68.
63. Ito N, Hayshi A, Lin W, et al. Music therapy in Parkinson's disease: improvement of parkinsonian gait and depression with rhythmic auditory stimulation. In Nakada N, ed. Integrated Human Brain Science. New York, NY: Elsevier Science, 2000; 435–43.
64. Azulay J, Mesure S, Amblard B, et al. Visual control of locomotion in Parkinson's disease. Brain 1999; 117: 1169–81.
65. Müller V, Mohr B, Rosin R, et al. Short-term effects of behavioral treatment on movement initiation and postural control in Parkinson's disease: a controlled clinical study. Mov Disord 1997; 12: 306–14.
66. Dam M, Tonin P, Casson S. Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's disease patients. Adv Neurol 1996; 69: 551–5.
67. Martin JP. The Basal Ganglia and Posture. London: Pitman, 1967.
68. Dietz, MA, Goetz CG, Stebbins GT. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord 1990; 5: 243–7.
69. Stern GM, Lander CM, Lees AJ. Akinetic freezing and trick movements in Parkinson's disease. J Neural Transm Suppl 1980; 16: 137–41.
70. Thaut MH, McIntosh GC, Rice RR, et al. Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Mov Disord 1996; 11: 193–200.
71. McIntosh GC, Brown SH, Rice RR, et al. Rhythmic auditory-motor facilitation of gait patterns in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 22–6.
72. Morris ME, Iansek R, Matyas TA, et al. Ability to modulate walking cadence remains intact in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 1532–4.
73. Behrman A, Teitelbaum P, Cauraugh J. Verbal instructional sets to normalize the temporal and spatial gait variables in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 65: 580–2.
74. Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007; 78: 134–40.
75. Jöbges M, Heuschkel G, Pretzel C, et al. Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1682–7.
76. Hirsch MA, Toole T, Maitland CG, et al. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. Arch Phys Med Rehabil 2003; 84(8): 1109–17.
77. Mirelman A, Maidan I, Herman T, et al. Virtual reality for gait training: can it induce motor learning to enhance complex walking and reduce fall risk in patients with Parkinson's disease? J Gerontol A Med Sci 2011; 66: 234–40.
78. Sato Y, Iwamoto J, Honda Y. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 22–6.
79. Shahed J, Jankovic J. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord 2001; 16: 114–18.
80. Ramig LO, Countryman S, O'Brien C, et al. Intensive speech treatment for patients with Parkinson's disease: short- and long-term comparison of two techniques. Neurology 1996; 47: 1496–504.
81. Ramig LO, Sapir S, Fox C, et al. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord 2001; 16: 79–83.
82. Robertson SJ, Thomson F. Speech therapy in Parkinson's disease: a study of the efficacy and long term effects of intensive treatment. Br J Disord Commun 1984; 19: 213–24.
83. Johnson JA, Prang TR. Speech therapy and Parkinson's disease: a review and further data. Br J Disord Commun 1990; 25: 183–94.
84. Bine JE, Frank EM, McDade HL. Dysphagia and dementia in subjects with Parkinson's disease. Dysphagia 1995; 10: 160–4.
85. Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson's disease. Dysphagia 1996; 11: 14–22.
86. Bushmann M, Dobmeyer SM, Leeker L, et al. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989; 39: 1309–14.
87. Nagaya M, Kachi T, Yamada T. Effect of swallowing training on swallowing disorders in Parkinson's disease. Scand J Rehabil Med 2000; 32: 11–15.
88. El Sharkawi A, Ramig L, Logemann JA, et al. Swallowing treatment and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study. J Neurol Neurosurg Psychiatry 2002; 72: 31–6.
89. Troche MS, Okun MS, Rosenbek JC, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST. Neurology 2010; 75: 1912–19.
90. Clarke CE, Gullaksen E, Macdonald S, et al. Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson's disease. Acta Neurol Scand 1998; 97: 27–35.
91. Ellgring H, Seiler S, Perleth B, et al. Psychosocial aspects of Parkinson's disease. Neurology 1993; 43: S41–4.
92. Montgomery EB, Lieberman A, Singh G, et al. Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. Am J Med 1994; 97: 429–35.
93. Oppenheim H. Über eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (dystonica lordotica progressiva, dystonia musculorum deformans). Neurologisches Zentralblatt 1911; 30: 1090–107.
94. Fahn S. The varied clinical expression of dystonia. Neurol Clin 1984; 2: 541–54.
95. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994; 117: 859–76.
96. Nutt JG, Muenter MD, Aronson A, et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov. Disord 1988; 2: 188–194.
97. Ozelius L, Kramer PL, Moskowitz CB, et al. Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron 1989; 2: 1427–34.
98. Bressman SB, de Leon D, Brin MF, et al. Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol 1989; 26: 612–20.
99. Flechter NA. The genetics of idiopathic torsion dystonia. J Med Genet 1990; 27: 409–12.
100. Kramer PL, Heiman GA, Gasser T, et al. The DYT1 gene on 9q34 is responsible for most cases of early limb-onset idiopathic torsion dystonia in non-Jews. Am J Genet 1994; 55: 468–75.
101. Pauls DL, Korczyn AD. Complex segregation analysis of dystonia pedigrees suggests autosomal dominant inheritance. Neurology 1990; 40: 1107–10.
102. Risch NJ, Bressmann SB, de Leon D, et al. Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet 1990; 46: 533–8.
103. Zilber N, Korczyn AD, Kahana E, et al. Inheritance of idiopathic torsion dystonia among Jews. J Med Genet 1984; 12: 13–20.
104. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17: 40–8.
105. Neuwald AF, Aravind L, Spouge JL, et al. AAA+: a class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. Genome Res 1999; 9: 27–43.
106. Torres GE, Sweeney AL, Beaulieu JM, et al. Effect of torsionA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsionA mutant. Proc Natl Acad Sci U S A 2004; 101: 15650–5.
107. O' Farrell CA, Martin KL, Hutton M, et al. Mutant torsinA interacts with tyrosine hydroxylase in cultured cells. Neuroscience 2009; 164: 1127–37.
108. McNaught KS, Kapustin A, Jackson T, et al. Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol 2004; 56: 540–7.
109. Ozelius LJ, Bressman SB. Genetic and clinical features of primary torsion dystonia. Neurobiol Dis 2011; 42: 127–35.
110. Berardelli A, Rothwell JC, Hallet M, et al. The pathophysiology of primary dystonia. Brain 1998; 121: 1195–212.
111. Deuschl G, Toro C, Matsumoto J, et al. Movement-related cortical potentials in writer's cramp. Ann Neurol 1995; 38: 509–14.
112. Ikoma K, Samii A, Mercuri B, et al. Abnormal cortical motor excitability in dystonia. Neurology 1996; 46: 1371–6.
113. Kaji R, Ikeda A, Ikeda T, et al. Physiological study of cervical dystonia. Task specific abnormality in contingent negative variation. Brain 1995; 118: 511–22.
114. Rothwell JC, Obeso JA, Day BL, et al. Pathophysiology of dystonias. Motor control mechanisms in health and disease. In Desmedt JE, ed. Motor Control Mechanisms in Health and Disease. New York, NY: Raven Press, 1983; 851–72.
115. Tolosa E, Montserrat L, Bayes A. Blink reflex studies in focal dystonias: enhanced excitability of brainstem interneurons in cranial dystonia and spasmodic torticollis. Mov Disord 1988; 3: 61–9.
116. Sohn YH, Hallett M. Disturbed surround inhibition in focal hand dystonia. Ann Neurol 2004; 56: 595–9.
117. Edwards MJ, Huang YZ, Wood NW, et al. Different patterns of electrophysiological deficits in manifesting and non-manifesting carriers of the DYT1 gene mutation. Brain 2003; 126: 2074–80.
118. Espay AJ, Morgante F, Purzner J, et al. Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol 2006; 59: 825–34.
119. Wissel J, Müller J, Poewe W. EMG for identification of dystonic, tremulous and spastic muscles and techniques for guidance of injections. In Moore P, Naumann M, eds. Handbook of Botulinum Toxin Treatment. Malden, MA: Blackwell Science, 2003; 76–98.
120. Yanagisawa N, Goto A. Dystonia musculorum deformans: analysis with electromyography. J Neurol Sci 1971; 13: 39–65.
121. Cohen LG, Hallett M. Hand cramps: clinical features and electromyographic patterns in a focal dystonia. Neurology 1988; 38: 1005–12.
122. Zhuang P, Li Y, Hallett M. Neuronal activity in the basal ganglia and thalamus in patients with dystonia. Clin Neurophysiol 2004; 115: 2542–57.
123. Byl NN, Merzenich MM, Cheung S, et al. A primate model for studying focal dystonia and repetitive strain injury: effects on the primary somatosensory cortex. Phys Ther 1997; 77: 269–84.
124. Bara-Jimenez W, Catalan MJ, Hallett M, et al. Abnormal somatosensory homunculus in dystonia of the hand. Ann Neurol 1998; 44: 828–31.
125. Edwards MJ, Huang YZ, Mir P, et al. Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. Mov Disord 2006; 21: 2181–6.
126. Wissel J, Müller J, Ebersbach G, et al. Trick maneuvers in cervical dystonia: investigation of movement- and touch-related changes in polymyographic activity. Mov Disord 1999; 14: 994–9.
127. Molloy FM, Carr TD, Zeuner KE, et al. Abnormalities of spatial discrimination in focal and generalized dystonia. Brain 2003; 126: 2175–82.
128. Fiorio M, Gambarin M, Valente EM, et al. Defective temporal processing of sensory stimuli in DYT1 mutation carriers: a new endophenotype of dystonia? Brain 2007; 130: 134–42.
129. Scontrini A, Conte A, Defazio G, et al. Somatosensory temporal discrimination in patients with primary focal dystonia. J Neurol Neurosurg Psychiatry 2009; 80: 1315–19.
130. Eidelberg D, Moeller JR, Antonini A, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 1998; 44: 303–12.
131. Argyelan M, Carbon M, Niethammer M, et al. Cerebellothalamo-cortical connectivity regulates penetrance in dystonia. J Neurosci 2009; 29: 9740–7.
132. Bonilha L, de Vries PM, Vincent DJ, et al. Structural white matter abnormalities in patients with idiopathic dystonia. Mov Disord 2007; 22: 1110–16.
133. Bonilha L, der Vries PM, Hird MW, et al. Disrupted thalamic prefrontal pathways in patients with idopathic dystonia. Parkinsonism Relat Disord 2009; 15: 64–7.
134. Carbon M, Kingsley PB, Su S, et al. Microstructural white matter changes in carriers of the SYT 1 gene mutation. Ann Neurol 2004; 56: 283–6.
135. Fabbrini G, Panatona P, Totaro P, et al. Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm. Eur J Neurol 2008; 15: 185–9.
136. Luft AR, Manto MU, Ben Taib NO. Modulation of motor cortex excitability by sustained peripheral stimulation: the interaction between the motor cortex and the cerebellum. Cerebellum 2005; 4: 90–6.
137. Manto MU. On the cerebello-cerebral interactions. Cerebellum 2006; 5: 286–8.
138. Molinari M, Filipponi V, Leggio MG. Neuronal plasticity of interrelated cerebellar and cortical networks. Neuroscience 2002; 111: 863–70.
139. Schrag A, Trimble M, Quinn N, et al. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain 2004; 127: 2360–72.
140. Segawa M, Nomura Y, Kase M. Diurnally fluctuating hereditary progressive dystonia. In Vinken PJ, Bruyn GW, Klawans HL, eds. Extrapyramidal Disorders. Vol 5. Amsterdam: Elsevier, 1986; 529–40.
141. Hallett M, Benecke R, Blitzer A, et al. Treatment of focal dystonias with botulinum neurotoxin. Toxicon 2009; 54: 628–33.
142. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004; 75: 951–7.
143. Simpson DM, Blitzer A, Brashear A, et al. Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1699–706.
144. Comella LC, Buchmann AS, Tanner CM, et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992; 42: 878–82.
145. Fietzek UM, Schroeder AS, Wissel J, et al. Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin. Mov Disord 2010; 25: 2225–8.
146. Molloy FM, Shill HA, Kaelin-Lang A, et al. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology 2002; 58: 805–7.
147. Schroeder AS, Berweck S, Lee SH, et al. Botulinum toxin treatment of children with cerebral palsy–a short review of different injection techniques. Neurotox Res 2006; 9: 189–96.
148. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004; 11: 361–70.
149. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst Rev 2005; 1:CD004312.
150. Gimenez-Roldan S, Mateo D, Martin M. Life-threatening cranial dystonia following trihexyphenidyl withdrawal. Mov Disord 2004; 18: 349–53.
151. Marsden CD, Marion MH, Quinn NP. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984; 47: 1166–73.
152. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986; 36: 160–4.
153. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996; 46: 1066–72.
154. Greene PE, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988; 3: 46–60.
155. Albright AL, Barry MJ, Shafton DH, et al. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001; 43: 652–7.
156. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355: 1978–90.
157. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005; 352: 459–67.
158. Cif L, El Fertit H, Vayssiere N, et al. Treatment of dystonic syndromes by chronic electrical stimulation of the internal globus pallidus. J Neurosurg Sci 2003; 47: 52–5.
159. Yianni J, Bain P, Giladi N, et al. Globus pallidus internus deep brain stimulation for dystonic conditions–a prospective audit. Mov Disord 2003; 18: 436–42.
160. Cif L, Vasques X, Gonzalez V, et al. Long-term follow-up of DYT 1 dystonia patients treated by deep brain stimulation: an open-label study. Mov Disord 2010; 25: 289–99.
161. Isaias IU, Altermann RL, Tagliati M. Deep brain stimulation for primary generalized dystonias: long-term outcomes. Arch Neurol 2009; 66: 465–70.
162. Andrews C, Aviles-Olmos I, Hariz M, et al. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010; 81: 1383–89.
163. Borggraefe I, Mehrkens JH, Telegravciska M, et al. Bilateral pallidal stimulation in children and adolescents with primary generalized dystonia-report of six patients and literature-based analysis of predictive outcomes variables. Brain Dev 2010; 32: 223–8.
164. Isaias IU, Alterman RL, Tagliati M. Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration. Brain 2008; 131: 1895–902.
165. Speelman JD, Contarino MF, Schuurman PR, et al. Deep brain stimulation for dystonia: patient selection and outcomes. Eur J Neurol 2010; 17: 102–6.
166. Vasques X, Cif L, Gonzalez V, et al. Factor predicting improvement in primary generalized dystonia treated by pallidal deep brain stimulation. Mov Disord 2009; 24: 846–53.
167. Capelle HH, Blahak C, Schrader C, et al. Chronic deep brain stimulation in patients with tardive dystonia without a history of major psychosis. Mov Disord 2010; 25: 1477–81.
168. Castelnau P, Cif L, Valente EM, et al. Pallidal stimulation improves pantothenate kinase associated neurodegeneration. Ann Neurol 2005; 57: 738–41.
169. Chang EF, Schrock LE, Starr PA, et al. Long-term benefit sustained after bilateral pallidal deep brain stimulation in patients with refractory tardive dystonia. Stereotact Funct Neurosurg 2010; 88: 304–10.
170. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009; 73: 53–8.
171. Krause M, Fogel W, Tronnier V, et al. Long-term benefit to pallidal deep brain stimulation in a case of dystonia secondary to pantothenate kinase-associated neurodegeneration. Mov Disord 2006; 21: 2255–7
172. Mikati MA, Yehya A, Darwish H, et al. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. Eur J Paediatr Neurol 2009; 13: 61–4.
173. Oyama G, Fernandez HH, Foote KD, et al. Differential response of dystonia and parkinsonism following globus pallidus internus deep brain stimulation in X-linked dystonia-parkinsonism (Lubag). Stereotact Funct Neurosurg 2010; 88: 329–3.
174. Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8: 709–17.
175. Wadia PM, Lim SY, Lozano AM, et al. Bilateral pallidal stimulation for X-linked dystonia parkinsonism. Arch Neurol 2010; 67: 1012–5.
176. Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, et al. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg 2003; 98: 1247–54.
177. Delnooz CCS, Horstink MWIM, Tijssen MA, et al. Paramedical treatment in primary dystonia: a systematic review. Mov Disord 2009; 15: 2187–98.
178. Duddy J. Lack of influence of EMG feedback in relaxation training for spasmodic torticollis. Clin Rehabil 1995; 9: 297–303.
179. Jahanshahi M, Satory G, Marsden CD. EMG biofeedback treatment of torticollis: a controlled outcome study. Biofeedback Self Regul 1991; 16: 413–48.
180. Tassorelli C, Mancini F, Balloni L, et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 2006; 21: 2240–43.
181. Berger H, van der Werf S, Horstink C, et al. Writer's cramp: restoration of striatal D2-binding after successful biofeedback-based sensorimotor training. Parkinsonism Relat Disord 2007; 13: 170–3.
182. Pohl C, Happe J, Klockgether T. Cooling improves the writing performance of patients with writer's cramp. Mov Disord 2002; 17: 1341–44.
183. Schenk T, Bauer B, Steidle B, et al. Does training improve writer's cramp? An evaluation of a behavioural treatment approach using kinematic analysis. J Hand Ther 2004; 17: 349–63.
184. Zeuner KE, Shill HA, Sohn YH, et al. Motor training as treatment in focal hand dystonia. Mov Disord 2005; 20: 335–41.
185. Muller J, Wissel J, Schuss D, et al. Visual biofeedback treatment of torticollis with a portable and easy-to-use personal training device. Mov Disord 2008; 1: S171.
186. Bleton JP. Spasmodic torticollis. Handbook of Rehabilitative Physiotherapy. Paris: Frison-Roche, 1994.
187. Samania N, Corato E, Tinazzi M, et al. The effect of two different rehabilitation treatments in cervical dystonia: preliminary results in four patients. Funct Neurol 2003; 18: 219–25.
188. Leis AA, Dimitrijevic MR, Delapasse JS, et al. Modification of cervical dystonia by selective sensory stimulation. J Neurol Sci 1992; 110: 79–89.
189. Schuele S, Lederman RJ. Long-term outcome of focal dystonia in string instrumentalists. Mov Disord 2004; 19: 43–8.
190. Byl NN, Nagajaran S, McKenzie AL. Effect of sensory discrimination training on structure and function in patients with focal hand dystonia: a case series. Arch Phys Med Rehabil 2003; 84: 1505–14.
191. Zeuner KE, Hallett M. Sensory training as treatment for focal hand dystonia: a 1-year follow-up. Mov Disord 2003; 18: 1044–7.
192. Tinazzi M, Zarattini S, Valeriani M, et al. Long-lasting modulation of human motor cortex following prolonged transcutaneous electrical nerve stimulation (TENS) of forearm muscles: evidence of reciprocal inhibition and facilitation. Exp Brain Res 2004; 161: 457–64.
193. Lefaucheur JP, Fenelon G, Menard-Lefaucheur I, et al. Low-frequency repetitive TMS of premotor cortex can reduce painful axial spasms in generalized secondary dystonia: a pilot study of three patients. Neurophysiol Clin 2004; 34: 141–5.
194. Murase N, Rothwell JC, Kaji R, et al. Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex modulates writer's cramp. Brain 2005; 128: 104–15.
195. Byl NN, Nagarajan SS, Merzenich MM, et al. Correlation of clinical neuromusculoskeletal and central somatosensory performance: variability in controls and patients with severe and mild focal hand dystonia. Neural Plast 2002; 9: 177–203.
196. Jankovic J. Tics and Tourette syndrome. In Jankovic JJ, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002; 311–30.
197. Zinzi P, Salmaso D, De Grandis R, et al. Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study. Clin Rehabil 2007; 21: 603–13.